

# Active Research Studies at Corewell Health West

2/9/2024

## Pediatrics

## Neurology

<b>ONYX</b>	<i>An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients with Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab</i>
<b>BHV2000-301 (SMA)</b>	<i>Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)</i>
<b>ROCHE Risediplam Pregnancy non-interventional safety study</b>	<i>Observational safety study to collect and analyze information on the use of risdiplam among pregnant women, and on pregnancy complications and birth outcomes in women exposed to risdiplam during pregnancy to fulfill FDA post marketing requirement.</i>
<b>BHV-3000-312</b>	<i>Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents = 6 to &lt; 18 years of age</i>
<b>BHV-3000-311</b>	<i>Phase 3 randomized, double blind, group sequential, placebo controlled assessing safety &amp; efficacy of rimegepant for treatment of migraine in those aged at least up to less than 18 years of age.</i>
<b>Zogenix CDKL5, ZX008</b>	<i>EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABEL EXTENSION</i>
<b>RD2021-0271 Cerebral Palsy Neurocrine</b>	<i>Phase 3, Randomized, Double-Blind, Placebo controlled assessing efficacy, safety, &amp; tolerability of Valbenazine for treatment of dyskinesia due to CP</i>
<b>Scholar Rock Phase 3</b>	<i>Phase 3 study for Spinal Muscular Atrophy (SMA)</i>

For information about research studies listed please use these contacts below:

Email: [researchassist@corewellhealth.org](mailto:researchassist@corewellhealth.org)

Phone: 616-391-3050

**RNS Response**

*A prospective non-randomized open label single arm pivotal study of RNS System treatment in patients with drug resistant focal onset seizures who are 12 through 17 years of age.*

---

**Lundbeck Migraine**

*Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine*

---

**Marinus**

*An inpatient Phase III Clinical Trial of a Novel Treatment Regimen for Refractory Status Epilepticus*

---

*For information about research studies listed please use these contacts below:*

*Email: [researchassist@corewellhealth.org](mailto:researchassist@corewellhealth.org)*

*Phone: 616-391-3050*